HLSHLS TherapeuticsHLS info
$2.42info1.85%24h
Global rank22670
Market cap$77.74M
Change 7d1.23%
YTD Performance-21.99%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    HLS Therapeutics (HLS) Stock Overview

    HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

    HLS Stock Information

    Symbol
    HLS
    Address
    10 Carlson CourtEtobicoke, ON M9W 6L2Canada
    Founded
    -
    Trading hours
    -
    Website
    https://www.hlstherapeutics.com
    Country
    🇨🇦 Canada
    Phone Number
    647-495-9000

    HLS Therapeutics (HLS) Price Chart

    -
    Value:-

    HLS Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.42
    N/A
    Market Cap
    $77.74M
    N/A
    Shares Outstanding
    32.07M
    N/A
    Employees
    99.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org